Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The study found no effect of center-to-center variation in fibroblast isolation, cell growth (Supplementary Documents Table S1), and cell aggregation values (Ln(A/N)) (Tables 1, 2).Patient population: Autopsy-validated fibroblasts-based peripheral diagnosis of Alzheimer’s disease and the presence of co-morbidity (N = 25).Sample ID/SourceAgeGenderMethodDisease duration (Yrs)Ln(A/N)MI diagnosisHistory and risk factorsAutopsy findings538 UTSW79MAutopsyN/A8.39ADN/APure Alzheimer’s disease; comorbidity = 0539 UTSW77MAutopsyN/A7.1ADN/APure Alzheimer’s disease; comorbidity = 0557 UTSW78MAutopsyN/A7.55ADN/AAlzheimer’s disease, lewy body dementia; comorbidity = 1AG05770 Coriell70MAutopsy7.58.11ADNonePure Alzheimer’s disease; comorbidity = 0AG08245 Coriell75MAutopsy79.78ADNoneAlzheimer’s disease, Parkinson’s disease, lewy body dementia; comorbidity = 2AG08527 Coriell61MAutopsyN/A7.57ADNoneAlzheimer’s disease, Parkinson’s disease; comorbidity = 1AG06840 Coriell56MGenetic49.2ADNonePure Alzheimer’s disease; comorbidity = 0AG04159 Coriell52FGenetic810.67ADComplex partial seizuresPure Alzheimer’s disease; comorbidity = 0AG06844 Coriell59MGenetic119.79ADProgressive memory impairment, diffuse slowing EEGPure Alzheimer’s disease; comorbidity = 0AG10788 Coriell87UnknownGenetic178.08ADNonePure Alzheimer’s disease; comorbidity = 0AG06869 Coriell60FAutopsy18.03ADVisuospatial disorientation, dyscalculia, diffuse slowing EEGPure Alzheimer’s disease; comorbidity = 0AG11368 Coriell77MAutopsyN/A7.16ADNonePure Alzheimer’s disease; comorbidity = 0AG05810 Coriell79FAutopsyN/A10.49ADNonePure Alzheimer’s disease; comorbidity = 0550 UTSW72MAutopsyN/A9.54ADNonePure Alzheimer’s disease; comorbidity = 0588 CRI78MAutopsyN/A7.85ADCerebrovascular accident, hypertension, benign prostatic hypertrophy, renal insufficiency, hemorrhoids, glaucomaAlzheimer’s Disease, Lewy Body Dementia, Lateral Ventricle Hydrocephalus; Comorbidity = 2658 CRI88FAutopsyN/A7.17ADCoronary artery disease, hypertension, anemia, glaucoma, perioral tremor, hysterectomyAlzheimer’s Disease, Frontotemporal Lobar Degeneration with TDP-43-Positive Inclusions; Comorbidity = 1568 CRI87FAutopsyN/A8.92ADHypercholesterolemia, coronary artery disease, hypertension, depression, serious head injuryAlzheimer’s Disease, Vascular Dementia, Multiple Remote Infarcts; Comorbidity = 2575 CRI55FAutopsyN/A8.92ADOsteoporosis, migraines, vitamin D deficiency, seizure disorderAlzheimer’s Disease, Frontotemporal Dementia, Marked Hydrocephalus; Comorbidity = 2589 CRI80FAutopsyN/A7.97ADVascular dementia, hypertension, hyperlipidemia, hyperhomocysteinemia, hyperthyroidism, anemia, depressionAlzheimer’s disease, vascular dementia, left occipital lobe infarct, multiple remote microinfarcts, lewy body disease; comorbidity = 4578 CRI70MAutopsyN/A7.91ADEarly-onset dementia, seizures, diverticulosis, attention deficit disorderAlzheimer’s disease, frontotemporal lobar degeneration with TDP-43-positive inclusions, lewy body disease, amygdalar pattern; comorbidity = 5563 CRI81FAutopsyN/A7.86ADAnxiety disorder, colon cancer, severe headaches, intracerebral hemorrhageAlzheimer’s disease, vascular dementia, right medial frontal-parietal cortex hemorrhage, remote right lateral prefrontal cortex hemorrhage, remote hemorrhagic infarct, multiple microinfarcts652 CRI86FAutopsyN/A7.85ADDiabetes, renal insufficiency, coronary artery disease, primary pulmonary hypertension, edema, atrial fibrillation, hyperlipidemia, hypothyroidism, anemia, osteopeniaAlzheimer’s disease, vascular dementia, multiple remote infarcts; comorbidity = 2599 WHM79MAutopsyN/A7.71ADDepressionAlzheimer’s disease, hydrocephalus; comorbidity = 1587 CRI85FAutopsyN/A7.61ADLabile hypertension, hypercholesterolemia, osteoporosis, colon adenocarcinoma, strokeAlzheimer’s disease, lewy body disease: neocortical type with alpha-synuclein-immunoreactive astrocytosis; comorbidity = 1590 CRI90FAutopsyN/A7.26ADLabile hypertension, hypercholesterolemia, hypothyroidism, osteoporosisAlzheimer’s disease, multiple cortical infarcts, moderate hydrocephalus; comorbidity = 2Autopsy/genetically validated skin fibroblasts-based peripheral diagnosis of non-Alzheimer’s disease dementia (N = 21).Sample IDAgeGenderNon-ADD diagnosisln(A/N)MI diagnosisRisk factorsAutopsy findingsND27760 Coriell55FParkinson’s disease (PD)4.6Non-ADDN/AParkinson’s diseaseGM02173 Coriell52FHuntington’s disease (HD)4.77Non-ADDN/AHuntington’s diseaseGM04715 Coriell40MHuntington’s disease (HD)4.93Non-ADDN/AHuntington’s diseaseGM05031 Coriell60MHuntington’s disease (HD)5.1Non-ADDN/AHuntington’s diseaseAG08395 Coriell85FParkinson’s disease (PD)5.15Non-ADDN/AParkinson’s disease, lewy bodiesGM00305 Coriell56FHuntington’s disease (HD)5.36Non-ADDN/AHuntington’s diseaseGM02165 Coriell67MHuntington’s disease (HD)5.4Non-ADDN/AHuntington’s diseaseGM04210 Coriell59MHuntington’s disease (HD)5.58Non-ADDN/AHuntington’s diseaseGM05030 Coriell56MHuntington’s disease (HD)5.61Non-ADDN/AHuntington diseaseGM04222 Coriell59MHuntington’s disease (HD)5.89Non-ADDN/AHuntington’s diseaseGM02167 Coriell59FHuntington’s disease (HD)5.91Non-ADDN/AHuntington’s diseaseND34265 Coriell62MParkinson’s disease (PD)6.01Non-ADDN/AParkinson’s diseaseGM04476 Coriell57MHuntington’s disease (HD)6.04Non-ADDN/AHuntington’s diseaseGM02038 Coriell22MSchizophrenia6.18Non-ADDN/ASchizophreniaGM04198 Coriell63FHuntington’s disease (HD)6.48Non-ADDN/AHuntington’s diseaseND31618 Coriell58FParkinson’s disease (PD)6.75Non-ADDN/AParkinson’s diseaseAG06274 Criell65FHuntington’s disease (HD)6.77Non-ADDN/AHuntington’s disease56467FCorticobasal degeneration (CBD)5.8Non-ADDHypertension, hyperlipidemia, osteoporosis, obesityCorticobasal degeneration, hydrocephalus574 CRI90FParkinson’s disease (PD)5.66Non-ADDMacular degeneration, osteoporosis, skin cancer, anemia, transient ischemic attacks, left cerebral artery aneurysmParkinson’s disease, multifocal atherosclerosis, arteriosclerosis586 CRI69MFrontotemporal lobar degeneration with TDP-43-positive inclusions (FTLD-TDP)6.5Non-ADDHypertension, headaches, cholecystectomyFrontotemporal lobar degeneration with TDP-43-positive inclusions, hydrocephalus, atherosclerosis of the basilar artery572 CRI60FParkinson’s disease (PD), Lewy body disease, neocortical distribution6.28Non-ADDHypertension, atrial fibrillationLewy body dementia, parkinson’s disease, minimal non-occlusive atherosclerosis of circle of willie

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Double-blind reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

An AD-biomarker, the Morphometric Imaging (MI) assay on cultured skin fibroblasts, was used in a double-blind, allcomers (ages 55 to 90) trial of 3 patient cohorts: AD dementia patients, N = 25, all autopsy confirmed, non-AD dementia patients, N = 21: all autopsy or genetically confirmed; and non-demented control (AHC) patients N = 27.

Source: Abstract.

We confirm that all methods were performed according to the relevant guidelines and regulations of the Declaration of Helsinki of Medical Research Involving Human Subjects.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients

Study design awaiting verification · Scientific Reports · 2022

Original publication title

Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients

Florin V. Chirila; Guang Xu; Dan Fontaine; Grant Kern; Tapan K. Khan; Jason Brandt; Yoshihiro Konishi; Gerhard Nebe-von-Caron; Charles L. White III; Daniel L. Alkon

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

A definitive diagnosis of Alzheimer’s disease (AD), even in the presence of co-morbid neuropathology (occurring in > 50% of AD cases), is a significant unmet medical need that has obstructed the discovery of effective AD therapeutics. An AD-biomarker, the Morphometric Imaging (MI) assay on cultured skin fibroblasts, was used in a double-blind, allcomers (ages 55 to 90) trial of 3 patient cohorts: AD dementia patients, N = 25, all autopsy confirmed, non-AD dementia patients, N = 21: all autopsy or genetically confirmed; and non-demented control (AHC) patients N = 27.

Fibroblasts cells isolated from 3-mm skin punch biopsies were cultured on a 3-D Matrigel matrix with movement dynamics quantified by image analysis. From counts of all aggregates (N) in a pre-defined field image and measures of the average area (A) of aggregates per image, the number-to-area ratios in a natural logarithmic form Ln(A/N) were determined for all patient samples. AD cell lines formed fewer large aggregates (cells clustered together) than non-AD or AHC cell lines. The cut-off value of Ln(A/N) = 6.98 was determined from the biomarker values of non-demented apparently healthy control (AHC) cases.

Unequivocal validation by autopsy, genetics, and/or dementia criteria was possible for all 73 patient samples. The samples were collected from multiple centers: four US centers and one center in Japan. The study found no effect of center-to-center variation in fibroblast isolation, cell growth, or cell aggregation values (Ln(A/N)). The autopsy-confirmed MI Biomarker distinguished AD from non-AD dementia (non-ADD) patients and correctly diagnosed AD even in the presence of other co-morbid pathologies at autopsy (True Positive = 25, False Negative = 0, False Positive = 0, True Negative = 21, and Accuracy = 100%.

Sensitivity and specificity were calculated as 100% (95% CI = 84 to 100.00%). From these findings, the MI assay appears to detect AD with great accuracy: even with abundant co-morbidity.

Authors’ abstract

A definitive diagnosis of Alzheimer’s disease (AD), even in the presence of co-morbid neuropathology (occurring in > 50% of AD cases), is a significant unmet medical need that has obstructed the discovery of effective AD therapeutics. An AD-biomarker, the Morphometric Imaging (MI) assay on cultured skin fibroblasts, was used in a double-blind, allcomers (ages 55 to 90) trial of 3 patient cohorts: AD dementia patients, N = 25, all autopsy confirmed, non-AD dementia patients, N = 21: all autopsy or genetically confirmed; and non-demented control (AHC) patients N = 27.

Fibroblasts cells isolated from 3-mm skin punch biopsies were cultured on a 3-D Matrigel matrix with movement dynamics quantified by image analysis. From counts of all aggregates (N) in a pre-defined field image and measures of the average area (A) of aggregates per image, the number-to-area ratios in a natural logarithmic form Ln(A/N) were determined for all patient samples. AD cell lines formed fewer large aggregates (cells clustered together) than non-AD or AHC cell lines. The cut-off value of Ln(A/N) = 6.98 was determined from the biomarker values of non-demented apparently healthy control (AHC) cases.

Unequivocal validation by autopsy, genetics, and/or dementia criteria was possible for all 73 patient samples. The samples were collected from multiple centers: four US centers and one center in Japan. The study found no effect of center-to-center variation in fibroblast isolation, cell growth, or cell aggregation values (Ln(A/N)). The autopsy-confirmed MI Biomarker distinguished AD from non-AD dementia (non-ADD) patients and correctly diagnosed AD even in the presence of other co-morbid pathologies at autopsy (True Positive = 25, False Negative = 0, False Positive = 0, True Negative = 21, and Accuracy = 100%.

Sensitivity and specificity were calculated as 100% (95% CI = 84 to 100.00%). From these findings, the MI assay appears to detect AD with great accuracy: even with abundant co-morbidity.

Publication and source details

Original title: Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients

Florin V. Chirila; Guang Xu; Dan Fontaine; Grant Kern; Tapan K. Khan; Jason Brandt; Yoshihiro Konishi; Gerhard Nebe-von-Caron; Charles L. White III; Daniel L. Alkon

Scientific Reports · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:56:39.167872+00:00

DOI: 10.1038/s41598-022-21796-y · PMC9626495